Evaluation of a Standardized Protocol for Thrombin Generation Assay
NCT ID: NCT03313531
Last Updated: 2019-01-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
9 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-04-15
Study Completion Date
2019-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is aims at determining the inter laboratory variation when using the thrombin generation assay calibrated automated thrombogram (TGA CAT). It is thus, not a clinical trial in its usual meaning. However, to achieve relevant test samples one patient will be treated with two different study drugs as part of the trial and therefore, approval by Läkemedelsverket is needed. Test plasma samples will be sent out to five participating centers in the Scandinavian countries (Gothenburg and Stockholm, Sweden, Århus Denmark, Oslo Norway and Helsinki Finland) and coefficients of variance (CV) and level of agreement will be analyzed. To obtain representative plasma samples with a wide range of thrombin generation capacity (TGC), blood samples will be collected from research persons that has given informed consent to participate in the study. To obtain plasma with low TGC, blood samples will be drawn from patients with severe hemophilia (n=4)(study group 1), to obtain plasma with normal TGC, blood samples will be drawn from healthy volunteers (n=3)(study group 2) and to obtain plasma with high TGC, plasma will be collected from healthy volunteers (n=3)(study group 3) that at previous measurements have been shown to have a TGC\>2SD of the median of the control population. Moreover, one patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions (Treated HA person). By taking repeated blood samples after administration, samples with a wide range of FVIII levels and TGC:s will be obtained. Moreover, the effect of using plasmas with low, normal and high TGC for normalization will be investigated. Plasma samples will be collected as soon as approval from the Swedish medical agency (SMA) has been obtained, we count on sending them to participating centers March 2017. All laboratory measurements, data analysis and report writing will be concluded before December 31 2017.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Feasibility Study to Collect Data in Patients With Haemophilia
NCT00798499
Hemophilia
COMPLETED
Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?
NCT02803502
Hemophilia
UNKNOWN
NA
Thrombin Generation Numerical Models Validation in Haemophilic Case
NCT02300519
Haemophilia B
Haemophilia A
COMPLETED
Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
NCT01505946
Severe Hemophilia A With Inhibitor
UNKNOWN
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
NCT02453542
Hemophilia
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Main goal The aim is to further improve the inter-laboratory variability for the TGA-CAT (Thrombin generation assay-calibrated automated thrombogram) method by using an elaborate standardization protocol and in extension making the use of large prospective multi-center studies a reality.
Goals of the project are:
* To determine the inter-laboratory variability by evaluating an enhanced standardized TGA-CAT protocol.
* To evaluate if the inter-laboratory variability of the TGA-CAT method is effected by administration of a recombinant FVIII product (Advate) in a person with severe hemophilia A
* To evaluate if the inter-laboratory variability of the TGA-CAT method is effected by administration of a long acting FVIII product (Adynovate) in a person with severe hemophilia A
* To evaluate three reference plasma´s ability, through normalization of data, to improve the lab-to-lab variability.
Introduction The TGA CAT method has proved its usefulness for multiple purposes including diagnosis and management of bleeding disorders (1, 2), detecting hyper coagulability (3, 4), and monitoring and characterization of oral anticoagulant drugs (5, 6). Most of these studies are single-center studies and large prospective multi-center studies are needed to further validate the results. These multi-center studies have proved to be hard to produce due to lack of standardization of the method. In the last couple of years several articles have addressed the problem with large inter-laboratory variability for the TGA-CAT method by presenting thoroughly worked-out standardization protocols. Focus has been put both on the method itself and its pre-analytical factors as well as the usage of reference plasmas (RP) for normalization of results. One article showed that the choice of RP for the normalization of results could greatly reduce the inter-lab variability and that certain RP have a better ability to do so (7).
Lately a number of recombinant Factor VIII (rFVIII) and IX (rFIX) drugs with prolonged half-life have been developed and are about to or even have reached the market. The length of the pro-longed activity of the drug differs between patients and a need for individual tailoring of the patient´s drug administration is obvious. Thrombin generation could prove to be an excellent tool in tailoring the optimal drug administration and monitoring the effect of the drug for each individual.
Methods and materials Thrombin generation Thrombin generation will be measured according to the method described by Hemker et al.(8): calibrated automated thrombogram (CAT, Thrombinoscope BV, Maastricht, the Netherlands).
Reagents PPP-reagent LOW (1 pM), PPP-reagent (5 pM), Thrombin Calibrator and FluCa-kit (TS31.00, TS30.00, TS20.00 and TS50.00, Thrombinoscope BV, Maastricht, The Netherlands) will be used in the test.
Samples Three different plasmas will be tested, normal plasma, hypo- and hypercoagulable plasma. Normal and hypercoagulable plasma will be pooled from 3 donors and hypocoagulable plasma will be collected from 4 donors. Hypocoagulable plasma will be collected from five haemophilia A (HA) patients regularly treated at the Malmö Coagulation Unit by taking 10 4.5 mL tubes of citrated blood at one occasion. Normal plasma will be collected from 3 co-workers at the same unit, each person donating 13 tubes of 4.5 mL citrated blood. Hypercoaguable plasma will be prepared from 3 healthy volunteers, shown to have TGA CAT parameter values \>2 SD of median by taking 13 tubes of 4.5 mL citrated blood. Plasma from one patient with severe HA patient that have been given FVIII-concentrates, Advate™ respectively the long-acting Adynovate™ at two separate occasions will also be tested. After informed consent the patient will be asked not to take his regular profylaxis dose for 72 hours. The patient will be given Advate™ and Adynovate™ respectively at 30 U/kg. The monitoring samples will be taken 1h, 8h, 24h, 36h and 48h (Advate™) and 1h, 24h, 36h, 48h and 72h (Adynovate™) after injection. At each time point 3 tubes of 4.5 mL blood will be taken.
Reference plasmas Siemens Control Plasma P diluted 1:5 will be used as hypocoaguable RP, HemosIL calibration plasma (Instrumentation Laboratory, Bedford, Ma, USA) will be used as Standard RP and as hypercoagable plasma PS-DP (protein S-deficiency plasma)(Enzyme research laboratories, South Bend, In, USA) will be used.
Statistical analysis Raw data will be collected and analyzed at the Coagulation Unit, Skåne University Hospital, Malmö. Each participating center will be matched with Malmö Coagulation unit in a test of agreement where Bland-Altman bias plot will be used. The mean, standard deviation (SD) and coefficient of variation (CV%) will be calculated for each center with and without normalization and displayed in a table. The Advate/ Adynovate elimination profiles will be plotted and multivariate repeated measurements analyses of variance including a general test for parallel curves, will be applied to evaluate differences between Centers in the elimination profiles.
Study design The study aims to evaluate the inter-laboratory variability of TGA-CAT performed TGT with a highly standardized protocol, how the use of RFs for normalization of data impact on variability of results and to evaluate the usefulness of TGA-CAT in monitoring prolonged FVIII drug administration. All Fluorometers of the participating center´s should be serviced and have temperature calibrated to 37 C prior start of the study. The latest software version must be installed (Thromboscope BV, Maastricht, The Netherlands, version V5.0.0.742). All laboratory equipment, pipettes, water baths, water purifiers, etc., needs to be calibrated. All plasmas, TGA-CAT reagents needed for the study will be administered and distributed to all participating centers by the Coagulation Unit, Malmö. An USB-memory stick containing a plate set-up scheme file and a video file covering critical pre-analytical and analytical steps will also be provided alongside the samples and reagents. Three pooled plasmas (normal, hypo- and hypercoaguable), three RF, five Adynovate and five Advate monitoring samples will be run five times on five different days by each participating center, following a scheme provided in the USB-memory stick, with two different triggers, PPP-reagent LOW (1 pM) and PPP-reagent (5 pM). Two test runs are scheduled each day to maximize RF and reagent usage. The reason for testing three different types of RF is the fact an earlier study results implied a better reduction of variability when using, for an example a hypocoaguable RF to hypocoaguable plasmas (9).
Goals of the project are:
* To determine the inter-laboratory variability by evaluating an enhanced standardized TGA-CAT protocol.
* To evaluate if the inter-laboratory variability of the TGA-CAT method is effected by administration of a recombinant FVIII product (Advate) in a person with severe hemophilia A
* To evaluate if the inter-laboratory variability of the TGA-CAT method is effected by administration of a long acting FVIII product (Adynovate) in a person with severe hemophilia A
* To evaluate three reference plasma´s ability, through normalization of data, to improve the lab-to-lab variability.
Introduction The TGA CAT method has proved its usefulness for multiple purposes including diagnosis and management of bleeding disorders (1, 2), detecting hyper coagulability (3, 4), and monitoring and characterization of oral anticoagulant drugs (5, 6). Most of these studies are single-center studies and large prospective multi-center studies are needed to further validate the results. These multi-center studies have proved to be hard to produce due to lack of standardization of the method. In the last couple of years several articles have addressed the problem with large inter-laboratory variability for the TGA-CAT method by presenting thoroughly worked-out standardization protocols. Focus has been put both on the method itself and its pre-analytical factors as well as the usage of reference plasmas (RP) for normalization of results. One article showed that the choice of RP for the normalization of results could greatly reduce the inter-lab variability and that certain RP have a better ability to do so (7).
Lately a number of recombinant Factor VIII (rFVIII) and IX (rFIX) drugs with prolonged half-life have been developed and are about to or even have reached the market. The length of the pro-longed activity of the drug differs between patients and a need for individual tailoring of the patient´s drug administration is obvious. Thrombin generation could prove to be an excellent tool in tailoring the optimal drug administration and monitoring the effect of the drug for each individual.
Methods and materials Thrombin generation Thrombin generation will be measured according to the method described by Hemker et al.(8): calibrated automated thrombogram (CAT, Thrombinoscope BV, Maastricht, the Netherlands).
Reagents PPP-reagent LOW (1 pM), PPP-reagent (5 pM), Thrombin Calibrator and FluCa-kit (TS31.00, TS30.00, TS20.00 and TS50.00, Thrombinoscope BV, Maastricht, The Netherlands) will be used in the test.
Samples Three different plasmas will be tested, normal plasma, hypo- and hypercoagulable plasma. Normal and hypercoagulable plasma will be pooled from 3 donors and hypocoagulable plasma will be collected from 4 donors. Hypocoagulable plasma will be collected from five haemophilia A (HA) patients regularly treated at the Malmö Coagulation Unit by taking 10 4.5 mL tubes of citrated blood at one occasion. Normal plasma will be collected from 3 co-workers at the same unit, each person donating 13 tubes of 4.5 mL citrated blood. Hypercoaguable plasma will be prepared from 3 healthy volunteers, shown to have TGA CAT parameter values \>2 SD of median by taking 13 tubes of 4.5 mL citrated blood. Plasma from one patient with severe HA patient that have been given FVIII-concentrates, Advate™ respectively the long-acting Adynovate™ at two separate occasions will also be tested. After informed consent the patient will be asked not to take his regular profylaxis dose for 72 hours. The patient will be given Advate™ and Adynovate™ respectively at 30 U/kg. The monitoring samples will be taken 1h, 8h, 24h, 36h and 48h (Advate™) and 1h, 24h, 36h, 48h and 72h (Adynovate™) after injection. At each time point 3 tubes of 4.5 mL blood will be taken.
Reference plasmas Siemens Control Plasma P diluted 1:5 will be used as hypocoaguable RP, HemosIL calibration plasma (Instrumentation Laboratory, Bedford, Ma, USA) will be used as Standard RP and as hypercoagable plasma PS-DP (protein S-deficiency plasma)(Enzyme research laboratories, South Bend, In, USA) will be used.
Statistical analysis Raw data will be collected and analyzed at the Coagulation Unit, Skåne University Hospital, Malmö. Each participating center will be matched with Malmö Coagulation unit in a test of agreement where Bland-Altman bias plot will be used. The mean, standard deviation (SD) and coefficient of variation (CV%) will be calculated for each center with and without normalization and displayed in a table. The Advate/ Adynovate elimination profiles will be plotted and multivariate repeated measurements analyses of variance including a general test for parallel curves, will be applied to evaluate differences between Centers in the elimination profiles.
Study design The study aims to evaluate the inter-laboratory variability of TGA-CAT performed TGT with a highly standardized protocol, how the use of RFs for normalization of data impact on variability of results and to evaluate the usefulness of TGA-CAT in monitoring prolonged FVIII drug administration. All Fluorometers of the participating center´s should be serviced and have temperature calibrated to 37 C prior start of the study. The latest software version must be installed (Thromboscope BV, Maastricht, The Netherlands, version V5.0.0.742). All laboratory equipment, pipettes, water baths, water purifiers, etc., needs to be calibrated. All plasmas, TGA-CAT reagents needed for the study will be administered and distributed to all participating centers by the Coagulation Unit, Malmö. An USB-memory stick containing a plate set-up scheme file and a video file covering critical pre-analytical and analytical steps will also be provided alongside the samples and reagents. Three pooled plasmas (normal, hypo- and hypercoaguable), three RF, five Adynovate and five Advate monitoring samples will be run five times on five different days by each participating center, following a scheme provided in the USB-memory stick, with two different triggers, PPP-reagent LOW (1 pM) and PPP-reagent (5 pM). Two test runs are scheduled each day to maximize RF and reagent usage. The reason for testing three different types of RF is the fact an earlier study results implied a better reduction of variability when using, for an example a hypocoaguable RF to hypocoaguable plasmas (9).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hemophilia A
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group 1
Patients with severe hemophilia A
Thrombin Generation Assay
Intervention Type
DIAGNOSTIC_TEST
Inter lab variation and level of agreement will be determined
Study group 2
Healthy volunteers
Thrombin Generation Assay
Intervention Type
DIAGNOSTIC_TEST
Inter lab variation and level of agreement will be determined
Study group 3
Healthy volunteers ) that at previous measurements have been shown to have a TGC\>2SD of the median of the control population.
Thrombin Generation Assay
Intervention Type
DIAGNOSTIC_TEST
Inter lab variation and level of agreement will be determined
Treated HA person
One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
Thrombin Generation Assay
Intervention Type
DIAGNOSTIC_TEST
Inter lab variation and level of agreement will be determined
Treatment with recombinant coagulation factor
Intervention Type
DRUG
To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thrombin Generation Assay
Inter lab variation and level of agreement will be determined
Intervention Type
DIAGNOSTIC_TEST
Treatment with recombinant coagulation factor
To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For patients with severe hemophilia A (study group 1)(n=4) that has not received any factor concentrate within 72 hours: Diagnosis of severe hemophilia, with regular check-ups at the hemophilia center at SUS, Malmö and willingness to participate
* For healthy controls (n=3) (study group 2): Willingness to participate
* For healthy controls with a documented high TGC (study group 3): Willingness to participate
* For healthy controls (n=3) (study group 2): Willingness to participate
* For healthy controls with a documented high TGC (study group 3): Willingness to participate
Exclusion Criteria
* For patients with severe hemophilia A (study group 1)(n=4) that has not received any factor concentrate within 72 hours: Intake of any other pharmaceutical product known to have an effect on the coagulation system the last 14 days, to the judgement of the including investigator
* For healthy controls (n=3) (study group 2): Any disorder known to affect the coagulation system and intake of any drug known to affect the coagulation system the last 14 days before blood sampling , to the judgement of the including investigator.
* For healthy controls with a documented high TGC (study group 3): Any disorder known to affect the coagulation system and intake of any drug known to affect the coagulation system within the last 14 days before blood sampling, to the judgement of the including investigator.
* For healthy controls (n=3) (study group 2): Any disorder known to affect the coagulation system and intake of any drug known to affect the coagulation system the last 14 days before blood sampling , to the judgement of the including investigator.
* For healthy controls with a documented high TGC (study group 3): Any disorder known to affect the coagulation system and intake of any drug known to affect the coagulation system within the last 14 days before blood sampling, to the judgement of the including investigator.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Sponsor Role
collaborator
Lund University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Astermark, MD PhD
Role: STUDY_DIRECTOR
Department of hematology, Skane University hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Coagulation Unit, department of translational medicine
Malmo, , Sweden
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Sweden
References
Explore related publications, articles, or registry entries linked to this study.
Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia. 2010 Jul;16 Suppl 5:85-92. doi: 10.1111/j.1365-2516.2010.02304.x.
Reference Type
BACKGROUND
Trossaert M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost. 2008 Mar;6(3):486-93. doi: 10.1111/j.1538-7836.2007.02861.x. Epub 2007 Nov 28.
Reference Type
BACKGROUND
Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost. 2006 Nov;96(5):562-7.
Reference Type
BACKGROUND
Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007 May;92(5):714-5. doi: 10.3324/haematol.10577.
Reference Type
BACKGROUND
Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011 May;127(5):457-65. doi: 10.1016/j.thromres.2011.01.001. Epub 2011 Jan 31.
Reference Type
BACKGROUND
Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res. 2011 Jan;127(1):29-34. doi: 10.1016/j.thromres.2010.07.024. Epub 2010 Sep 17.
Reference Type
BACKGROUND
Dargaud Y, Luddington R, Gray E, Lecompte T, Siegemund T, Baglin T, Hogwood J, Regnault V, Siegemund A, Negrier C. Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study. Thromb Res. 2010 Apr;125(4):353-6. doi: 10.1016/j.thromres.2009.11.012. Epub 2009 Nov 26.
Reference Type
BACKGROUND
Perrin J, Depasse F, Lecompte T; French-speaking CAT group and under the aegis of GEHT; French-speaking CAT group (all in France unless otherwise stated):; French-speaking CAT group all in France unless otherwise stated. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thromb Res. 2015 Jul;136(1):125-30. doi: 10.1016/j.thromres.2014.12.015. Epub 2014 Dec 24.
Reference Type
BACKGROUND
Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15. doi: 10.1159/000071636.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TGA1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
NCT01205724
COMPLETED
PHASE1
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
ACTIVE_NOT_RECRUITING
PHASE2
TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia
NCT02781766
UNKNOWN
NA
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
NCT03587116
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
NCT02622321
COMPLETED
PHASE3
Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography
NCT03002480
WITHDRAWN
NA
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
NCT02061033
UNKNOWN
Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders
NCT02324517
UNKNOWN
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
NCT01562457
COMPLETED
PHASE1
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
NCT02035384
COMPLETED
Monitoring of Anti-TFPI in Hemophilia
NCT07101926
RECRUITING
Emicizumab in Acquired Hemophilia A
NCT04188639
COMPLETED
PHASE2
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
NCT01580293
COMPLETED
PHASE2/PHASE3
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
NCT03315455
COMPLETED
PHASE3
Study Evaluating ReFacto AF in Severe Hemophilia A
NCT00037544
COMPLETED
PHASE3
A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
NCT02049099
COMPLETED
ATHN 2: Factor Switching Study
NCT02546622
COMPLETED
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
NCT00168051
WITHDRAWN
PHASE4
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
NCT01480180
COMPLETED
PHASE3
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
NCT03020160
COMPLETED
PHASE3
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
NCT03741881
COMPLETED
Clot Formation and Clot Stability in Patients With Severe Haemophilia A
NCT00279578
COMPLETED
NA